Pathogenesis of lower urinary tract symptoms in benign prostatic hyperplasia

Abstract

BACKGROUND: Lower urinary tract symptoms (LUTS) in men are most commonly associated with prostate pathology, and voiding symptoms in the presence of an enlarged prostate are a key factor in favor of surgical treatment. However, the etiology of LUTS is multifactorial, and these symptoms are not specific to prostate diseases. One potential etiological factor contributing to LUTS in men is radicular and visceral manifestations of degenerative spinal changes.

AIM: To assess the role of degenerative spinal diseases in the pathogenesis of LUTS in patients with benign prostatic hyperplasia (BPH).

MATERIALS AND METHODS: This study analyzed data from 168 men (mean age 64.1 ± 1.2 years, range 58–83) who underwent surgery for BPH to investigate the potential causes of persistent LUTS postoperatively. In addition to general clinical and urological assessments, all patients underwent an active clinical-neurological examination to identify chronic neurological conditions.

RESULTS: Postoperative examination of BPH patients with persistent LUTS revealed neurological pathology in 62.5% of cases, which could independently contribute to urinary dysfunction. In 47.02% of cases, these pathologies were degenerative spinal changes with radicular and autonomic manifestations. The predominant manifestation of LUTS in patients with degenerative spinal changes was overactive bladder, with scores ranging from 8 to 19 points (mean 13.11 ± 0.02) on the Overactive Bladder Questionnaire (OAB-q). Treatment of concomitant neurological pathology led to the resolution or significant alleviation of LUTS and improved quality of life in patients with persistent urinary disorders following BPH surgery.

CONCLUSIONS: Persistent irritative LUTS after surgical treatment of BPH may be associated with concomitant degenerative spinal changes with radicular and autonomic manifestations. Targeted treatment of these conditions, primarily in the form of myofascial and radicular syndromes, significantly reduces the severity of LUTS.

Keywords

lower urinary tract symptoms / benign prostatic hyperplasia / BPH / degenerative spinal changes

References

[1] Ficarra V, Rossanese M, Zazzara M, et al. The role of inflammation in lower urinary tractsymptoms (LUTS) due to benign prostatic hyperplasia (BPH) and its potential impact on medical therapy. Curr Urol Rep. 2014;15(12):463. doi: 10.1007/s11934-014-0463-9

[2] Ficarra V., Rossanese M., Zazzara M., et al. The role of inflammation in lower urinary tractsymptoms (LUTS) due to benign prostatic hyperplasia (BPH) and its potential impact on medical therapy // Curr Urol Rep 2014. Vol. 15, N 12. P. 463. doi: 10.1007/s11934-014-0463-9

[3] Hunter DJ, McKee CM, Black NA, Sanderson CF. Urinary symptoms: prevalence and severity in British men aged 55 and over. J Epidemiol Community Health. 1994;48(6):569–75. doi: 10.1136/jech.48.6.569

[4] Hunter D.J., McKee C.M., Black N.A., Sanderson C.F. Urinary symptoms: prevalence and severity in British men aged 55 and over // J Epidemiol Community Health. 1994. Vol. 48, N 6. P. 569–575. doi: 10.1136/jech.48.6.569

[5] Madersbacher S, Haidinger G, Temml C, Schmidbauer CP. Prevalence of lower urinary tract symptoms in Austria as assessed by an open survey of 2,096 men. Eur Urol. 1998;34(2):136–141. doi: 10.1159/000019699

[6] Madersbacher S., Haidinger G., Temml C., Schmidbauer C.P. Prevalence of lower urinary tract symptoms in Austria as assessed by an open survey of 2,096 men // Eur Urol. 1998. Vol. 34, N 2. P. 136–141. doi: 10.1159/000019699

[7] Chepurov AV, Shkolnikov ME, Bulantsev DYu. Benign prostatic hyperplasia: determination of indications for surgical treatment. The Journal of General Medicine. 2007;(2):12–16. (In Russ.) EDN: MSYQFT

[8] Чепуров А.В., Школьников М.Е., Буланцев Д.Ю. Доброкачественная гиперплазия предстательной железы: определение показаний к оперативному лечению // Лечебное дело. 2007. № 2. С. 12–16. EDN: MSYQFT

[9] Al-Shukri SH, Amdiy RE, Kuzmin IV. Decrease of urinary bladder contractility in patients with benign prostate hyperplasia. Urology Reports (St. Petersburg). 2011;1(1):3–8. EDN: PJJDLH doi: 10.17816/uroved57650

[10] Аль-Шукри С.Х., Амдий Р.Э., Кузьмин И.В. Снижение сократимости мочевого пузыря у больных доброкачественной гиперплазией предстательной железы // Урологические ведомости. 2011. Т. 1, № 1. C. 3–8. EDN: PJJDLH doi: 10.17816/uroved57650

[11] Kuo HC. Analysis of the pathophysiology of lower urinary tract symptoms in patients after prostatectomy. Urol Int. 2002;68(2): 99–104. doi: 10.1159/000048427

[12] Kuo H.C. Analysis of the pathophysiology of lower urinary tract symptoms in patients after prostatectomy // Urol Int. 2002. Vol. 68, N 2. P. 99–104. doi: 10.1159/000048427

[13] Shormanov IS, Kulikov SV, Soloviev AS, et al. Analysis of the prevalence of lower urinary tract symptoms in elderly and elderly men. In: Proceedings of the XXII Congress of the Russian Urological Society. Moscow, September 14–17, 2022. Moscow; 2022. P. 556. (In Russ.) EDN: BFOCWH

[14] Шорманов И.С., Куликов С.В., Соловьев А.С., и др. Анализ распространенности симптомов нижних мочевых путей у мужчин пожилого и старческого возраста. В кн.: Материалы ХХII Конгресса Российского общества урологов. Москва, 14–17 сентября 2022 г. Москва, 2022. С. 556. EDN: BFOCWH

[15] Chapple CR, Roehrborn CG. A shifted paradigm for the further understanding, evaluation, and treatment of lower urinary tract symptoms in men: focus on the bladder. Eur Urol. 2006;49(4): 651–658. doi: 10.1016/j.eururo.2006.02.018

[16] Chapple C.R., Roehrborn C.G. A shifted paradigm for the further understanding, evaluation, and treatment of lower urinary tract symptoms in men: focus on the bladder // Eur Urol. 2006. Vol. 49, N 4. P. 651–658. doi: 10.1016/j.eururo.2006.02.018

[17] Kirpatovsky VI, Wise IS, Mkrtchyan KG, et al. Pelvic organ ischemia as an independent pathogenetic factor in the development of benign prostatic hyperplasia and bladder dysfunction. Bulletin of Experimental Biology and Medicine. 2014;158(12):676–680. (In Russ.) EDN: TCABQB

[18] Кирпатовский, В.И. Мудрая И.С., Мкртчян К.Г., и др. Ишемия тазовых органов как самостоятельный патогенетический фактор развития доброкачественной гиперплазии предстательной железы и дисфункции мочевого пузыря // Бюллетень экспериментальной биологии и медицины. 2014. Т. 158, № 12. С. 676–680. EDN: TCABQB

[19] Sevryukov FA, Sorokin DA, Karpukhin IV, et al. Transurethral enucleation of prostate (TUEB) — new option in bipolar endoscopic surgery of BPH. Experimental and Clinical Urology. 2012;(2):34–36. EDN PDARMH

[20] Севрюков Ф.А., Сорокин Д.А., Карпухин И.В., и др. Трансуретральная энуклеация предстательной железы (TUEB) — новый метод биполярной эндоскопической хирургии ДГПЖ // Экспериментальная и клиническая урология. 2012. № 2. С. 34–36. EDN PDARMH

[21] Mustafaev AT, Kyzlasov PS, Dianov MP, et al. Surgical treatment of benign prostatic hyperplasia: the past and the present. Urology Reports (St. Petersburg). 2019;9(1):47–56. EDN: ICSZAV doi: 10.17816/uroved9147-56

[22] Мустафаев А.Т., Кызласов П. С., Дианов М. П., и др. Хирургическое лечение доброкачественной гиперплазии предстательной железы: прошлое и настоящее // Урологические ведомости. 2019. Т. 9, № 1. С. 47–56. EDN: ICSZAV doi: 10.17816/uroved9147-56

[23] Martov AG, Merinov DS, Pavlov DA, et al. New endoscopic technologies in the treatment of benign prostatic hyperplasia. Urologiia. 2003;(2):56–64. (In Russ.)

[24] Мартов А.Г., Меринов Д.С., Павлов Д.А., и др. Новые эндоскопические технологии в лечении доброкачественной гиперплазии предстательной железы // Урология. 2003. № 2. С. 56–64.

[25] Kamalov AA, Gushchin BL, Dorofeev SD, et al. Modern aspects of surgical treatment of benign prostatic hyperplasia. Urologiia. 2004;(1):30–34. (In Russ.)

[26] Камалов АА, Гущин Б.Л., Дорофеев С.Д., и др. Современные аспекты оперативного лечения доброкачественной гиперплазии предстательной железы // Урология. 2004. № 1. С. 30–34.

[27] www.umedp.ru [Internet]. Pushkar D.Yu. “Successful” transurethral resection of the prostate in the Russian Federation. In: XVII Congress of the Russian Society of Urology «Effective Pharmacotherapy. Urology and Nephrology». 2017. No. 2 (2). Available from: https://umedp.ru/articles/print/11949/

[28] www.umedp.ru [Электронный ресурс]. Пушкарь Д.Ю. «Успешная» трансуретральная резекция простаты в РФ. В кн.: XVII Конгресс Российского общества урологов «Эффективная фармакотерапия. Урология и Нефрология». 2017. № 2 (2). Режим доступа: https://umedp.ru/articles/print/11949/

[29] Al-Shukri SH, Giorgobiani TG, Amdiy RE, Al-Shukri AS. Urinary dysfunction in patients with unsatisfactory results of surgical treatment of benign prostatic hyperplasia. Grekov’s Bulletin of Surgery. 2017;176(6):66–70. EDN: YKHOZW

[30] Аль-Шукри С.Х., Гиоргобиани Т.Г., Амдий Р.Э., АльШукри А.С. Нарушения мочеиспускания у больных с неудовлетворительными результатами хирургического лечения доброкачественной гиперплазии предстательной железы // Вестник хирургии им. И.И. Грекова. 2017. Т. 176, № 6. С. 66–70. EDN: YKHOZW doi: 10.24884/0042-4625-2017-176-6-66-70

[31] Campbell RA, Gill BC. Medication discontinuation following transurethral prostatectomy: an unrecognized effectiveness measure? Current Urology Reports. 2020;21(12):61. doi: 10.1007/s11934-020-01015-9

[32] Campbell R.A., Gill B.C. Medication discontinuation following transurethral prostatectomy: an unrecognized effectiveness measure? // Current Urology Reports. 2020. Vol. 21, N 12. P. 61. doi: 10.1007/s11934-020-01015-9

[33] Cornu JN, Ahyai S, Bachmann A, et al. A systematic review and meta-analysis of functional outcomes and complications following transurethral procedures for lower urinary tract symptoms resulting from benign prostatic obstruction: an update. Eur Urol. 2015;67(6):1066–1096. doi: 10.1016/j.eururo.2014.06.017

[34] Cornu J.N., Ahyai S., Bachmann A., et al. A systematic review and meta-analysis of functional outcomes and complications following transurethral procedures for lower urinary tract symptoms resulting from benign prostatic obstruction: an update // Eur Urol. 2015. Vol. 67, N 6. P. 1066–1096. doi: 10.1016/j.eururo.2014.06.017

[35] Simanov RN, Amdiy RE, Al-Shukri SK, et al. Effectiveness of treatment of detrusor overactivity after transurethral resection of benign prostate hyperplasia. Urology reports (St. Petersburg). 2023;13(1):5–13. EDN: GUAKSQ doi: 10.17816/uroved192493

[36] Симанов Р.Н., Амдий Р.Э., Аль-Шукри С.Х., и др. Эффективность лечения гиперактивности детрузора после трансуретральной резекции доброкачественной гиперплазии предстательной железы // Урологические ведомости. 2023. Т. 13, № 1. С. 5–13 EDN: GUAKSQ doi: 10.17816/uroved192493

[37] Simanov RN, Amdiy RE, Kuzmin IV. Features of detrusor function disorders in patients with dysuria in the long period after transurethral resection of the prostate. Urology reports (St. Petersburg). 2024;14(1):35–44. EDN: HRJIIS doi: 10.17816/uroved619917

[38] Симанов Р.Н., Амдий Р.Э., Кузьмин И.В. Особенности нарушений функции детрузора у пациентов с дизурией в отдаленном периоде после трансуретральной резекции предстательной железы // Урологические ведомости. 2024. Т. 14, № 1. С. 35–44. EDN: HRJIIS doi: 10.17816/uroved619917

[39] Amdii RE, Simanov RN. Frequency and pathogenesis of urinary disorders after transurethral resection of the prostate gland. In: Proceedings of the 7th Scientific and Practical Conference of Urologists of the North-West Federal District. Saint Petersburg, April 12–13, 2024. 17 p. (In Russ.) EDN: BHOQQC

[40] Амдий Р.Э., Симанов Р.Н. Частота и патогенез расстройств мочеиспускания после трансуретральной резекции предстательной железы. В кн.: Материалы 7-й Научно-практической конференции урологов Северо-Западного федерального округа. Санкт-Петербург, 12–13 апреля 2024 г. 17 c. EDN: BHOQQC

[41] Filippova ES, Bazhenov IV, Zyryanov AV. Zhuravlev VN. The epidemiology of neurogenic urination disciordeis. Experimental and Clinical Urology. 2020;(3):25–33. EDN: FCOPJC doi: 10.29188/2222-8543-2020-12-3-25-33

[42] Филиппова Е.С., Баженов И.В., Зырянов А.В., Журавлев В.Н. Эпидемиология нейрогенных нарушений мочеиспускания // Экспериментальная и клиническая урология. 2020. № 3. С. 25–33. EDN: FCOPJC doi: 10.29188/2222-8543-2020-12-3-25-33

[43] Liao L, Madersbacher H. Neurourology. Theory and practice. Springer; 2019. 583 p. doi: 10.1007/978-94-017-7509-0

[44] Liao L., Madersbacher H. Neurourology. Theory and practice. Springer, 2019. 583 p. doi: 10.1007/978-94-017-7509-0

[45] Zharkov PL, Zharkov AP, Bubnovsky SM. Lumbar pain. Moscow; 2001. 143 p.

[46] Жарков П.Л., Жарков А.П., Бубновский С.М. Поясничные боли. Москва, 2001. 143 с.

[47] Popelyansky YaYu. Orthopedic neurology (vertebronneurology): Manual for doctors. Moscow: MEDpress-Inform; 2003. 670 p. (In Russ.) EDN: QLEJUT

[48] Попелянский Я.Ю. Ортопедическая неврология (вертеброневрология): Руководство для врачей. Москва: МЕДпресс-информ, 2003. 670 с. EDN: QLEJUT

[49] Kasyan GR, Krivoborodov GG, Shamalov NA, Pushkar DYu. Practical neurourology. Moscow; 2018. 56 p. (In Russ.)

[50] Касян Г.Р., Кривобородов Г.Г., Шамалов Н.А., Пушкарь Д.Ю. Практическая нейроурология. Москва, 2018. 56 с.

[51] Siracusa G, Sparacino A, Lentini VL. Neurogenic bladder and disc disease: a brief review. Curr Med Res Opin. 2013;29(8):1025–1031. doi: 10.1185/03007995.2013.807788

[52] Siracusa G., Sparacino A., Lentini V.L. Neurogenic bladder and disc disease: a brief review // Curr Med Res Opin. 2013. Vol. 29, N 8. P. 1025–1031. doi: 10.1185/03007995.2013.807788

[53] Pinheiro JS, de Jesus SFC, Apahaza GHS, et al. 15-item Roland-Morris Disability Questionnaire (RMDQ-15): structural and criterion validity on patients with chronic low back pain. BMC Musculoskelet Disord. 2022;23(1):978. doi: 10.1186/s12891-022-05953-y

[54] Pinheiro J.S., de Jesus S.F.C., Apahaza G.H.S., et al. 15-item Roland-Morris Disability Questionnaire (RMDQ-15): structural and criterion validity on patients with chronic low back pain // BMC Musculoskelet Disord. 2022. Vol. 23, N 1. P. 978. EDN: FRETFE doi: 10.1186/s12891-022-05953-y

[55] Hashimoto H, Komagata M, Nakai O, et al. Discriminative validity and responsiveness of the Oswestry Disability Index among Japanese outpatients with lumbar conditions. Eur Spine J. 2006;15(11): 1645–16450. doi: 10.1007/s00586-005-0022-7

[56] Hashimoto H., Komagata M., Nakai O., et al. Discriminative validity and responsiveness of the Oswestry Disability Index among Japanese outpatients with lumbar conditions // Eur Spine J. 2006. Vol. 15, N 11. P. 1645–16450. EDN: IGXRGV doi: 10.1007/s00586-005-0022-7

[57] Kontogiannis S, Athanasopoulos A, Tsagkarakis M, Kontodimopoulos N. Psychometric evaluation of the Overactive Bladder Questionnaire (OAB-q) for measuring quality of life and clinical implications in Greek patients with overactive bladder. Int Urogynecol J. 2022;33(11):3035–3043. doi: 10.1007/s00192-021-04991-9

[58] Kontogiannis S., Athanasopoulos A., Tsagkarakis M., Kontodimopoulos N. Psychometric evaluation of the Overactive Bladder Questionnaire (OAB-q) for measuring quality of life and clinical implications in Greek patients with overactive bladder // Int Urogynecol J. 2022. Vol. 33, N 11. P. 3035–3043. EDN: QIXXIW doi: 10.1007/s00192-021-04991-9

[59] Roland M, Fairbank J. The Roland-Morris disability questionnaire and the oswestry disability questionnaire. Spine (Phila Pa 1976). 2000;25(24):3115–31124. doi: 10.1097/00007632-200012150-00006

[60] Roland M., Fairbank J. The Roland-Morris disability questionnaire and the oswestry disability questionnaire // Spine (Phila Pa 1976). 2000. Vol. 25, N 24. P. 3115–31124. doi: 10.1097/00007632-200012150-00006

[61] Khabirov FA, Bikmullin TA, Galyamov DL. Features of the course of lumbar osteochondrosis in patients operated on the removal of herniated intervertebral disc. Vertebronneurology. 2000;(1–2):27–31. (In Russ.)

[62] Хабиров Ф.А., Бикмуллин Т.А., Галямов Д.Л. Особенности течения поясничного остеохондроза у больных, оперированных по поводу удаления грыжи межпозвонкового диска // Вертеброневрология. 2000. № 1–2. С. 27–31.

[63] Drivontov BV, Gamanovich AI, Loginov VG. Viscero-vertebral pain syndrome of lumbar osteochondrosis (pathogenesis, clinic, treatment). Minsk: BGMU; 2016. 24 p.

[64] Дривонтов Б.В., Гаманович А.И., Логинов В.Г. Висцеро-вертебральный болевой синдром поясничного остеохондроза (патогенез, клиника, лечение). Минск: БГМУ, 2016. 24 с.

[65] Xu L, Zhang Y, Min X, et al. Refractory lower urinary tract symptoms in patients with lumbar disc hernia relieved by non-surgical treatment. World J Urol. 2021;39(5):1597–1605. doi: 10.1007/s00345-020-03330-9

[66] Xu L., Zhang Y., Min X., et al. Refractory lower urinary tract symptoms in patients with lumbar disc hernia relieved by non-surgical treatment // World J Urol. 2021. Vol. 39, N 5. P. 1597–1605. doi: 10.1007/s00345-020-03330-9

RIGHTS & PERMISSIONS

Eco-Vector